Fred Roeder, Health Economist and Managing Director of the Consumer Choice Center
Last week when visiting Davos during the World Economic Forum, Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, casually walked down the main street of the small alpine town without a worry in his face. At that moment, his organization saw no international threat in the Chinese-originating coronavirus. This was despite worrying reports from China and questionable legitimacy of the official numbers provided by the Chinese Communist government.
Since then, the WHO has apologized and corrected their initial assessment. The virus is now seen as a high risk to the East Asian region and globally.
History is repeating itself once more During the Ebola crisis in West Africa in 2014, it took the WHO months to finally declare an emergency. They were too tied up in fighting non-communicable diseases.
The most important task, and the founding reason, of the WHO should be combating international diseases and coordination of rapid crisis responses. But unfortunately the Geneva-based agency spends much of its time with topics such as road safety, secondhand smoke, vaping, and the renovation of their own offices.
Next week the body’s executive board will convene from February 3rd-8th. Instead of revamping their agenda and fully focusing on how to contain the coronavirus, the current agenda prioritizes many other points before dealing with an international crisis response.
While our taxes should be spent on keeping us safe from this virus, the WHO’s board will instead spend the first couple of days discussing ideological ideas of universal healthcare reforms in emerging markets and how to limit patents of pharmaceutical companies. This is apparently more important for an agency that spends 10% of its 2 billion annual budget than figuring out how to effectively combat killer viruses.
Once you scroll down the agenda of the meeting, you will finally find crisis response next to topics such as ‘aging in health’ and ‘renovation of the WHO Headquarters’.
So instead of putting the very real and scary threat of the Coronavirus first, the board members will prioritize how to limit incentives for the private sector to come up with treatments and vaccinations for the virus. Scrapping patents and limiting intellectual property rights are key pillars of the WHO’s priorities these days. Limiting patents is seen as a solution to curb health costs in emerging markets. For the international governmental organization, this seems to be an easier way than actually calling out their member states who often increase drug prices by 10-40% through import taxes and sales taxes paid by patients.
Chinese patients alone pay over 5 billion dollars a year on tariffs for drugs they import. In times of a massive health crisis in China, the WHO should urge the Chinese government to drop all of these tariffs momentarily.
After the Ebola outbreak in 2014, the private sector quickly reacted and several companies developed and delivered Ebola-vaccines at the same time. Now we need a similarly quick response for the coronavirus. Therefore, the WHO should not limit the innovative potential of the pharmaceutical industry but encourage them to invest in finding vaccines.
The coronavirus has already taken too many human lives and the situation will worsen. International trade and the global economy can also easily take a massive hit from a worsening situation. Instead of debating how to make the WHO’s offices better looking for natural light, its board should focus 100% on how to contain and combat the coronavirus. That’s priority number one.
Over and over, we see how the WHO fails to respond in an accurate and timely manner to such pandemics. It is high time for the agency to focus on its core mission: Protecting us from trans-national diseases.
